-
2023.04.27
At the 2023 ASCO Annual meeting, the latest information on the Japan Phase II study of Nanvuranlat (development code: JPH203) will be announced. Nanvuranlat is a novel L-type amino acid transporter 1 (LAT1) inhibitor for refractory biliary tract cancer patients.
-
What's new
- Financing total 2.4 billion yen completed through a third-party allotment of new shares (Round E) 2023/10/05
- J-Pharma Receives Award from the National Multiple Sclerosis Society to Develop JPH034 as a Potential Treatment for Progressive Multiple Sclerosis 2023/10/05
- Notice of Transition to Company with Audit and Supervisory Committee and New Board of Directors Appointments 2023/10/02
- Notice of Board of Directors Appointments 2023/06/28
- Haruki Kusaka, Director of Clinical Development Dept. receives Outstanding Leadership Award at HEALTH 2.0 Conference (Dubai, UAE) 2023/06/26
-
Monthly
- 2023.10 (3)
- 2023.06 (3)
- 2023.05 (1)
- 2023.04 (1)
- 2023.03 (2)
- 2023.01 (3)
- 2022.12 (2)
- 2022.05 (1)
- 2022.04 (1)
- 2022.01 (1)
- 2021.11 (1)
- 2021.07 (1)
- 2021.03 (2)
- 2021.02 (1)
- 2021.01 (2)
- 2020.07 (1)
- 2020.06 (1)
- 2019.12 (1)
- 2019.04 (1)
- 2018.12 (1)
- 2018.07 (1)
- 2018.05 (1)
- 2018.03 (1)
- 2018.01 (1)
- 2017.09 (1)
- 2016.05 (1)
- 2015.11 (1)
- 2015.04 (1)
- 2015.02 (1)